Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast
New data for the vaccine candidate from Oxford and AstraZeneca have stoked enthusiasm that countermeasures against COVID-19 are within reach. On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss the latest readout from one of the COVID-19 vaccine front-runners, how biopharma companies are managing back to work and Blueprint’s diagnostic deal with Roche.
Senior Editor Lauren Martz explains results from AstraZeneca plc (LSE:AZN; NYSE:AZN) and the University of Oxford, who she says will likely move forward with a two-dose schedule for their adenoviral vaccine following a Phase I/II readout, a decision that could shift timelines, availability and tolerability of the vaccine (see “Two-dose Schedule, Infection Levels May Shift Timelines for AZ-Oxford Vaccine”). ...